Ming Guo
Founder bei Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
Profil
Ming Guo was the founder of Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
(founded in 2009) where he holds the title of Chief Operating Officer and Ascentage Pharma Group International Co., Ltd.
(founded in 2009) where he holds the title of President.
Dr. Guo is also the founder of Sino-American Biotechnology & Pharmaceutical Professional.
Currently, Dr. Guo holds the position of Director at Ascentage International Ltd.
and Member at The BayHelix Group.
Dr. Guo's former positions include Independent Director at Porton Pharma Solutions Ltd.
(2012-2016), Principal at Monsanto Co., Research Associate at the University of California San Diego, and Vice President-Manufacturing at Ascenta Therapeutics, Inc. (2005-2010).
Dr. Guo's education includes a doctorate degree from the University of California San Diego (1991), an undergraduate degree from Beijing Normal University (1982), and a graduate degree from Peking Union Medical College (1985).
Aktive Positionen von Ming Guo
| Unternehmen | Position | Beginn |
|---|---|---|
Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
 Jiangsu Yasheng Pharmaceutical Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Jiangsu Yasheng Pharmaceutical Development Co. Ltd. develops and produces pharmaceutical products. It focuses on research and development of structure-based molecule for cancer drugs. The company was founded by Dajun Yang, Ming Guo, and Shaomeng Wang in 2009 and is headquartered in Hong Kong. | Founder | 01.01.2009 |
| Sino-American Biotechnology & Pharmaceutical Professional | Founder | - |
| The BayHelix Group | Corporate Officer/Principal | - |
| Ascentage International Ltd. | Director/Board Member | - |
Ehemalige bekannte Positionen von Ming Guo
| Unternehmen | Position | Ende |
|---|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Founder | 31.10.2021 |
| PORTON PHARMA SOLUTIONS LTD. | Director/Board Member | 22.03.2016 |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Corporate Officer/Principal | 01.01.2010 |
| University of California San Diego | Corporate Officer/Principal | - |
| MONSANTO | Corporate Officer/Principal | - |
Ausbildung von Ming Guo
| University of California San Diego | Doctorate Degree |
| Beijing Normal University | Undergraduate Degree |
| Peking Union Medical College | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| PORTON PHARMA SOLUTIONS LTD. | Health Technology |
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Health Technology |
| Private Unternehmen | 6 |
|---|---|
Monsanto Co.
 Monsanto Co. Wholesale DistributorsDistribution Services Monsanto Co. engages in the provision of agricultural products to farmers. It provides other seed companies with genetic material and biotechnology traits for their seed brands. The company was founded by John F. Queeny in 1901 and is headquartered in St. Louis, MO. | Distribution Services |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Health Technology |
| The BayHelix Group | |
Jiangsu Yasheng Pharmaceutical Development Co. Ltd.
Jiangsu Yasheng Pharmaceutical Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Jiangsu Yasheng Pharmaceutical Development Co. Ltd. develops and produces pharmaceutical products. It focuses on research and development of structure-based molecule for cancer drugs. The company was founded by Dajun Yang, Ming Guo, and Shaomeng Wang in 2009 and is headquartered in Hong Kong. | Health Technology |
| Sino-American Biotechnology & Pharmaceutical Professional | |
| Ascentage International Ltd. |